Evaluation of Conventional Cardiovascular Risk Factors and Ordinal Coronary Artery Calcium Scoring in a Lung Cancer Screening Cohort

Overview

Journal J Cardiovasc Dev Dis

Specialty Cardiology & Vascular Diseases

Date 2024 Jan 22

PMID 38248886

Authors

Piotr Kasprzyk

Aleksandra Undrunas

Katarzyna Dziadziuszko

Robert Dziedzic

Krzysztof Kuziemski

Edyta Szurowska

Witold Rzyman

Tomasz Zdrojewski

Affiliations

Soon will be listed here.

Abstract

(1) Background: Lung cancer screening (LCS) consists of low-dose computed tomography (LDCT) results to reduce lung cancer-related mortality. The LCS program has a unique opportunity to impact CVD mortality by providing tools for CVD risk assessment and implementing preventative strategies. In this study, we estimated standardized CVD risk (SCORE) and assessed the prevalence of coronary artery calcium (CAC) in a Polish LCS cohort. (2) Methods: In this observational study, 494 LCS participants aged 50-79 years with a cigarette smoking history of at least 30 pack-years were included. Medical history, anthropometric measurements, blood pressure measurements, serum glucose, and cholesterol levels were assessed in one visit. CVD risk assessment using SCORE tables was performed. The results were compared to the general population (NATPOL 2011 study). On LDCT scans, CAC was classified using an Ordinal Score ranging from 0 to 12. (3) Results: The prevalence of classic cardiovascular risk factors was very high. Among study participants, 83.7% of men and 40.7% of women were classified with a very high CVD SCORE risk (>10%). CAC was reported in 190 (47%) participants. Calcification was categorized as severe (CAC ≥ 4) in 84 (21%) participants. (4) Conclusions: Due to the high cardiovascular risk, intensive preventive strategies are recommended for LCS participants.

Citing Articles

Can Artificial Intelligence Help Us in the Evaluation of Coronary Artery Calcification Scores by Acting as a Prognosticator in Patients That Are Operated on Due to Non-Small Cell Lung Cancer? A Pivotal Study.

Marjanski T, Chmielecki M, Klein-Awerjanow K, Cytawa W, Ciepialowska P, Bilyk A J Clin Med. 2024; 13(21).

PMID: 39518718 PMC: 11546565. DOI: 10.3390/jcm13216579.

References

Jha P, Peto R . Global effects of smoking, of quitting, and of taxing tobacco. N Engl J Med. 2014; 370(1):60-8. DOI: 10.1056/NEJMra1308383. View

Church T, Black W, Aberle D, Berg C, Clingan K, Duan F . Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013; 368(21):1980-91. PMC: 3762603. DOI: 10.1056/NEJMoa1209120. View

Pedersen J, Ashraf H, Dirksen A, Bach K, Hansen H, Toennesen P . The Danish randomized lung cancer CT screening trial--overall design and results of the prevalence round. J Thorac Oncol. 2009; 4(5):608-14. DOI: 10.1097/JTO.0b013e3181a0d98f. View

Jacobs P, Gondrie M, van der Graaf Y, de Koning H, Isgum I, van Ginneken B . Coronary artery calcium can predict all-cause mortality and cardiovascular events on low-dose CT screening for lung cancer. AJR Am J Roentgenol. 2012; 198(3):505-11. DOI: 10.2214/AJR.10.5577. View

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M . 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31(7):1281-357. DOI: 10.1097/01.hjh.0000431740.32696.cc. View

Oudkerk M, Devaraj A, Vliegenthart R, Henzler T, Prosch H, Heussel C . European position statement on lung cancer screening. Lancet Oncol. 2017; 18(12):e754-e766. DOI: 10.1016/S1470-2045(17)30861-6. View

Budoff M, Nasir K, Kinney G, Hokanson J, Barr R, Steiner R . Coronary artery and thoracic calcium on noncontrast thoracic CT scans: comparison of ungated and gated examinations in patients from the COPD Gene cohort. J Cardiovasc Comput Tomogr. 2010; 5(2):113-8. PMC: 3075464. DOI: 10.1016/j.jcct.2010.11.002. View

Ostrowski M, Marjanski T, Dziedzic R, Jelitto-Gorska M, Dziadziuszko K, Szurowska E . Ten years of experience in lung cancer screening in Gdańsk, Poland: a comparative study of the evaluation and surgical treatment of 14 200 participants of 2 lung cancer screening programmes†. Interact Cardiovasc Thorac Surg. 2019; 29(2):266–274. DOI: 10.1093/icvts/ivz079. View

Greenland P, Blaha M, Budoff M, Erbel R, Watson K . Coronary Calcium Score and Cardiovascular Risk. J Am Coll Cardiol. 2018; 72(4):434-447. PMC: 6056023. DOI: 10.1016/j.jacc.2018.05.027. View

10.

Pletcher M, Tice J, Pignone M, McCulloch C, Callister T, Browner W . What does my patient's coronary artery calcium score mean? Combining information from the coronary artery calcium score with information from conventional risk factors to estimate coronary heart disease risk. BMC Med. 2004; 2:31. PMC: 515311. DOI: 10.1186/1741-7015-2-31. View

11.

Rasmussen T, Kober L, Abdulla J, Holst Pedersen J, Wille M, Dirksen A . Coronary artery calcification detected in lung cancer screening predicts cardiovascular death. Scand Cardiovasc J. 2015; 49(3):159-67. DOI: 10.3109/14017431.2015.1039572. View

12.

Pastorino U, Silva M, Sestini S, Sabia F, Boeri M, Cantarutti A . Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Ann Oncol. 2019; 30(7):1162-1169. PMC: 6637372. DOI: 10.1093/annonc/mdz117. View

13.

Zhao Y, Xie X, de Koning H, Mali W, Vliegenthart R, Oudkerk M . NELSON lung cancer screening study. Cancer Imaging. 2011; 11 Spec No A:S79-84. PMC: 3266562. DOI: 10.1102/1470-7330.2011.9020. View

14.

Ostrowski M, Marczyk M, Dziedzic R, Jelitto-Gorska M, Marjanski T, Pisiak S . Lung cancer survival and comorbidities in lung cancer screening participants of the Gdańsk screening cohort. Eur J Public Health. 2019; 29(6):1114-1117. DOI: 10.1093/eurpub/ckz052. View

15.

van Iersel C, de Koning H, Draisma G, Mali W, Scholten E, Nackaerts K . Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer. 2006; 120(4):868-74. DOI: 10.1002/ijc.22134. View

16.

Moyer V . Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014; 160(5):330-8. DOI: 10.7326/M13-2771. View

17.

Hurt R, Ebbert J, Muggli M, Lockhart N, Robertson C . Open doorway to truth: legacy of the Minnesota tobacco trial. Mayo Clin Proc. 2009; 84(5):446-56. PMC: 2676127. DOI: 10.1016/S0025-6196(11)60563-6. View

18.

Wood D . National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Lung Cancer Screening. Thorac Surg Clin. 2015; 25(2):185-97. DOI: 10.1016/j.thorsurg.2014.12.003. View

19.

Aberle D, Adams A, Berg C, Clapp J, Clingan K, Gareen I . Baseline characteristics of participants in the randomized national lung screening trial. J Natl Cancer Inst. 2010; 102(23):1771-9. PMC: 2994863. DOI: 10.1093/jnci/djq434. View

20.

Piepoli M, Hoes A, Agewall S, Albus C, Brotons C, Catapano A . 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by.... Eur Heart J. 2016; 37(29):2315-2381. PMC: 4986030. DOI: 10.1093/eurheartj/ehw106. View